VERACYTE, INC.
VCYTLoading price...
Overview
Previous Close--
Open--
Ask--
Bid--
Day's Range -
52 Week Range -
PE Ratio(TTM)--
Market Cap--
Volume--
Avg. Volume--
12 Months Earnings88.01M
12 Months Revenue541.74M
Profit/Loss
| PARTICULARS | TTM | 2025 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|---|
| Operating Revenue | 541.74M | 517.14M | 479.13M | 445.76M | 361.05M | 296.54M |
| Cost of Revenue | 157.56M | 154.61M | 152.09M | 147.62M | 131.37M | 120.86M |
| Gross Profit | 384.18M | 362.53M | 327.04M | 298.14M | 229.68M | 175.68M |
| Operating Expenses | 286.16M | 284.25M | 293.01M | 278.63M | 247.13M | 211.02M |
| Profit after Tax (Net Income) | 88.01M | 66.35M | 26.34M | 24.14M | -74.40M | -36.56M |
Company Profile
Sector: Healthcare
Industry: Diagnostics & Research
HQ Location: South San Francisco, United States
Website: https://www.veracyte.com
CEO & Director: Mr. Marc A. Stapley
Employees: 755
About Company:
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.